Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seegene's diarrhoea test approved in Canada

This article was originally published in Clinica

Executive Summary

Health Canada has approved Seegene’s Seeplex Diarrhea-V ACE detection test. The PCR-based diagnostic detects 10 bacteria and four viruses that cause diarrhoea, including Salmonella and Campylobacter species and Clostridium difficile toxin B, and the rotavirus and norovirus. This helps physicians to select the most appropriate treatment for patients at the earliest stage. The test provides results in around six hours, faster than traditional methods for diagnosis of diarrhoea such as microscopy, enzyme-linked immunosorbent assays (ELISAs) and stool culture. These techniques are also more difficult to carry out and can lack sensitivity and specificity, Rockville, Maryland-based Seegene says. The test is already CE marked for sale in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT045203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel